Skip to main content

Effectiveness of antiviral treatment in preventing death in severe hospitalised influenza cases over six seasons

  • A. Domínguez (a1) (a2), A. Romero-Tamarit (a2), N. Soldevila (a1) (a2), P. Godoy (a2) (a3), M. Jané (a2) (a3), A. Martínez (a2) (a3), N. Torner (a1) (a2) (a3), J.A. Caylà (a2) (a4), C. Rius (a2) (a4) and the Surveillance of Hospitalized Cases of Severe Influenza in Catalonia Working Group...

We investigated the predictors of neuraminidase inhibitor (NAI) treatment in severe hospitalised influenza cases and the association between antiviral treatment and mortality. An observational epidemiological study was carried out in Catalonia (Spain) during 2010–2016 in patients aged ⩾18 years. Severe hospitalised cases of laboratory-confirmed influenza requiring hospitalisation were included. We collected demographic, virological and clinical characteristics. Mixed-effects logistic regression was used to estimate crude and adjusted odds ratio (aOR). We included 1727 hospitalised patients, of whom 1577 (91.3%) received NAI. Receiving NAI ⩽48 h after onset of clinical symptoms (aOR 0.37, 95% confidence interval (CI) 0.22–0.63), ⩽3 days (aOR 0.49, 95% CI 0.30–0.79) and ⩽5 days (aOR 0.50, 95% CI 0.32–0.79) was associated with a reduction in deaths. In patients admitted to the intensive care unit (ICU) (595; 34.5%), treatment ⩽48 h (aOR 0.32, 95% CI 0.14–0.74), ⩽3 days (aOR 0.44, 95% CI 0.20–0.97) and ⩽5 days (aOR 0.45, 95% CI 0.22–0.96) was associated with a reduction in deaths. Receiving treatment >5 days after onset of clinical symptoms was not associated with the reduction in deaths in hospitalised patients or those admitted to the ICU. NAI treatment of hospitalised patients with severe confirmed influenza was effective in avoiding death, mainly when administered ⩽48 h after symptom onset, but also when no more than 5 days had elapsed.

Corresponding author
Author for correspondence: A. Romero-Tamarit, E-mail:
Hide All
1.World Health Organization. Questions and answers on immunization and vaccine safety. Available at
2.World Health Organization. Fact sheet on influenza. Available at
3.Treanor, JJ (2015) Influenza (including avian influenza and swine influenza. In Bennet, JE, Dolin, R and Blaser, MJ (eds). Principles and Practice of Infectious Diseases, 8th edn., Philadelphia, PA: Elsevier, pp. 20002024.
4.Harper, SA, et al. (2009) Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Disease Society of America. Clinical Infectious Disease 48, 10031032.
5.Spagnuolo, PJ, et al. (2016) Effects of antiviral treatment on influenza-related complications over four influenza season: 2006–2010. Current Medical Research and Opinion 32, 13991407.
6.Lindegren, ML, et al. (2015) Antiviral treatment among older adults hospitalized with influenza, 2006–2012. PLoS ONE 10, e0121952.
7.Agència de Salut Pública de Catalunya. Pla d'actuació a Catalunya enfront d'una infecció per virus de la grip en fase post-pandèmica. Available at (Accessed 28 November 2017).
8.McGeer, A, et al. (2007) Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clinical Infectious Disease 45, 15681575.
9.Martin, ET (2017) Use of neuraminidase inhibitors for treatment of severe influenza: times are changing. Clinical Infectious Disease 64, 368369.
10.Michiels, B, et al. (2013) The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS ONE 8, e60348.
11.Hsu, J, et al. (2012) Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Annals of Internal Medicine 156, 512524.
12.Lindegren, ML and Schaffner, W (2014) Treatment with neuraminidase inhibitors for high-risk patients with influenza: why is adherence to antiviral treatment recommendations so low? The Journal of Infection Disease 210, 510513.
13.Agència de Salut Pública de Catalunya. Estratègia de Vigilància dels casos greus produïts per la infecció pel virus de la grip. Available at (Accessed 28 November 2017).
14.Centro Nacional de Epidemiología. Vigilancia de casos graves hospitalizados confirmados de virus de la gripe. Available at (Accessed 28 November 2017).
15.Suwannakarn, K, et al. (2008) Typing (A/B) and subtyping (H1/H3/H5) of influenza A viruses by multiplex real-time RT-PCR assays. Journal of Virological Methods 152, 2531.
16.Katz, MH (2011) Multivariable Analysis, 3rd edn., Cambridge, CBG: Cambridge University Press, pp. 8892.
17.Appiah, GD, et al. (2017) Increased antiviral treatment among hospitalized children and adults with laboratory-confirmed influenza, 2010–2015. Clinical Infectious Disease 64, 364367.
18.Fernández, S, et al. (2012) Analysis of confirmed severe cases of influenza in the first season after pandemic. Medicina Clinica 139, 8487.
19.Maruyama, T, et al. (2016) Outcomes and prognostic features of patients with influenza requiring hospitalization and receiving early antiviral therapy: a prospective multicentre cohort study. Chest 149, 526534.
20.Shah, NS, et al. (2015) Severe influenza in 33 US hospitals, 2013–2014: complication and risk factors for death in 507 patients. Infection Control and Hospital Epidemiology 36, 12511260.
21.Xu, C, et al. (2013) Characteristics of hospitalized cases with influenza A (H1N1)pdm09 infection during first winter season of post-pandemic in China. PLoS ONE 8, e55016.
22.Rolfes, MA, et al. (2016) Respiratory viral testing and influenza antiviral prescriptions during hospitalization for acute respiratory illness. Open Forum Infectious Disease 3, ofv216.
23.Gutiérrez-Pizarraya, A, et al. (2012) Unexpected severity of cases of influenza B infection in patients that required hospitalization during first postpandemic wave. The Journal of Infection 65, 423430.
24.Hiba, V, et al. (2011) Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study. The Journal of Antimicrobial Chemotherapy 66, 11501155.
25.Lee, N, et al. (2010) Outcomes of adults hospitalised with severe influenza. Thorax 65, 510515.
26.Delgado-Rodríguez, M, et al. (2012) Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors. The Journal of Antimicrobial Chemotherapy 67, 17391745.
27.Muthuri, SG, et al. (2014) Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza H1N1pdm09 virus infection: a meta-analysis of individual participant data. The Lancet. Respiratory Medicine 2, 395404.
28.Rodríguez, A, et al. (2011) Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. The Journal of Antimicrobial Chemotherapy 66, 11401149.
29.Lee, N, et al. (2013) Influenza virus load in hospitalized patients. Hong Kong Medical Journal 19, 1518.
30.Louie, JK, et al. (2012) Treatment with neuraminidase inhibitors for critically ill patients with influenza A(H1N1)pdm09. Clinical Infectious Disease 55, 11981204.
31.Yu, H, et al. (2010) Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. British Medical Journal 341, c4779.
32.Ayscue, P, et al. (2014) Influenza-associated intensive-care unit admissions and deaths – California, September 29, 2013–January 18, 2014. MMWR Morbidity and Mortality Weekly Report 63, 143147.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Type Description Title
Supplementary materials

Domínguez et al. supplementary material
Tables S1-S3

 Word (19 KB)
19 KB


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed